FAB13: the historic Made in Italy pharmaceutical companies confirm themselves as the driving force of the national economy
The new Edison Foundation Report was presented in Milan: the thirteen Italian pharmaceutical multinationals that have their “heart and brain” in the country are growing
The latest Edison Foundation Report dedicated to the FAB13, the historic multinationals, with Italian capital, of Made in Italy pharmaceuticals, part of Farmindustria, was presented Monday 17th at the Edison Foundation. In a dialogue between Professor Marco Fortis, Vice President of the Edison Foundation, and Doctor Sebastiano Barisoni, Executive Deputy Director of Radio24, the results obtained by the Italian pharmaceutical industry in the last 20 years were analyzed in terms of growth in production, employment, research and development, innovation and exports.
The Italian pharmaceutical industry stands out as one of the driving sectors of Made in Italy, and the FAB13 – which include Alfasigma, Abiogen Pharma, Angelini Pharma, Chiesi Farmaceutici, Dompé Farmaceutici, I.B.N. Savio, Italfarmaco, Kedrion, Menarini, Molteni, Neopharmed Gentili, Recordati and Zambon – confirm their centrality in the country’s innovation, research and economic growth.
According to the Report, these companies recorded a 12% growth in 2023, reaching a total turnover of 16.8 billion euros, with exports that reached 6.2 billion euros (+19% compared to the previous year).
The thirteen Italian pharmaceutical companies, in fact, are recognized as one of the “Seven” sectors of excellence of Made in Italy, alongside strategic sectors such as mechanics, food and fashion.
